Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

David R. Wise, MD, PhD
Published: Wednesday, Feb 14, 2018



David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).
SELECTED
LANGUAGE


David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x